Stelexis Therapeutics

Drugs targeting pre-cancerous stem cells

STLX1022 RD oncology

Stelexis Therapeutics is discovering novel targets aimed at the tumor’s origin to transform cancer treatment. Current cancer treatments often do not remove the pre-cancer and cancer stem cells that are the primary cause of cancer progression. To eliminate these cells, Stelexis is identifying targets on cancerous stem cells, aided by seminal discoveries at leading academic institutions. This involves the use of their platform, TumorOrigin, which enables unprecedented study of these cells for drug discovery. The platform utilizes large banks of patient-derived samples to discover novel, druggable targets. With their platform, Stelexis hopes to overcome former limitations to study these pre-cancerous cells for therapeutic benefit.